SCHEMBL1491868

SCHEMBL1491868

COc1ccc(O[C@H]2O[C@H](C)[C@H](O)[C@H](O)[C@H]2OC(=O)CCC(C)=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 2/20 0.40
ALDH1A1 P00352 2/20 0.39
NR1H3 Q13133 1/20 0.36
CYP3A4 P08684 2/20 0.36
HPGD P15428 1/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
MAOA P21397 1/20 0.35
SLC6A2 P23975 1/20 0.35
RAB9A P51151 1/20 0.35
SLC6A3 Q01959 1/20 0.35
PDE5A O76074 2/20 0.35
KDM1A O60341 1/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491946 0.84 FGF2 (0.44) LGALS8ALDH1A1CYP3A4HPGDLMNA
SCHEMBL1491902 0.81 MMP1 (0.34) LGALS8ALDH1A1CYP3A4LMNASMN1; SMN2
SCHEMBL4189072 0.75 CYP3A4 (0.49) LGALS8ALDH1A1CYP3A4LMNATP53
SCHEMBL1491947 0.74 CA12 (0.51) ALDH1A1NR1H3HPGDKDM4ENPC1
SCHEMBL1491881 0.74 CA12 (0.51) ALDH1A1NR1H3HPGDKDM4ENPC1
SCHEMBL1491923 0.73 FGF2 (0.43) LGALS8ALDH1A1CYP3A4LMNANPC1
SCHEMBL7957798 0.72 ALDH1A1 (0.43) LGALS8ALDH1A1NPC1MAPTRAB9A
SCHEMBL1491891 0.70 CYP3A4 (0.41) LGALS8ALDH1A1CYP3A4LMNASMN1; SMN2
SCHEMBL23121475 0.70 LGALS8 (0.50) LGALS8CYP3A4NPC1TP53RAB9A
SCHEMBL13755879 0.69 CYP3A4 (0.54) ALDH1A1CYP3A4LMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7901687-B2 Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections ETH ZURICH (CH) 2011-03-08 US disclosed
US-20090155299-A1 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections SCHWEIZERISCHES TROPENINSTITUT (CH) 2009-06-18 US disclosed
EP-2012821-A2 ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS ETH Zürich (CH) 2009-01-14 EP disclosed
WO-2007125089-A2 ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS ETH Zürich (CH) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155299-A1 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections ANTXR2, CERT1, DAD1 LGALS8 1200/4885ALDH1A1 2915/4885NR1H3 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.